Researchers to expand malaria vaccine study after initial trial yields encouraging results

NewsGuard 100/100 Score

Encouraged by early results of a study of an experimental malaria vaccine involving 45 children in Burkina Faso, researchers led by Pierre Druilhe at the Pasteur Institute in Paris are set to expand the clinical trial, resulting in a larger study involving 800 children in Mali, BBC News reports. The initial trial aimed "to test the safety of the vaccine but this follow up study found that children who received it had an incidence of the disease three to four times lower than children who did not," BBC writes.

"Around a hundred different malaria vaccine candidates have been developed to date but the MSP3 vaccine tested in Burkina Faso is only the second one to show a substantial level of protection against the illness," the news service writes. "There have been too many claims of effective vaccines so we have to remain very cautious. It has to be confirmed and we have started on work to do that confirmation," Druilhe said, according to BBC (McGrath, 9/21).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MSU team creates a promising vaccine candidate for antibiotic-resistant bacteria